Avoidance of infusion reactions in response to cetuximab using hydrocortisone sodium succinate

DOI
  • Nagano Hiromi
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Jimura Tomohiro
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Miyamoto Yumi
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Iuch Hiroyuki
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Umakoshi Mizuo
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Makise Takao
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Kawabata Masaki
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima
  • Kurono Yuichi
    Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima

Bibliographic Information

Other Title
  • セツキシマブ治療におけるインフュージョン・リアクション軽減の試み

Search this article

Description

Objective: Targeted monoclonal antibodies such as cetuximab are a promising treatment option for patients with cancer, but are associated with a risk of development of infusion reactions (IRs). Cetuximab has a different spectrum of adverse events compared to other antineoplastic drugs due to differences in its mechanisms of action. The aim of this study was to investigate suppression of IRs related to cetuximab using hydrocortisone sodium succinate.<br>Methods: The initial dose of cetuximab was 400 mg/m2. Infusion reactions were assessed based on the NCI-CTCAE criteria (ver. 4.0). Patients were divided into an early group treated with diphenhydramine (Restamin®) and dexamethasone sodium phosphate (Dexart®) and a late group that additionally received hydrocortisone sodium succinate (Solu-cortef®). Rates of infusion reactions in response to the first dose of cetuximab in each group were compared with the Mann-Whitney U test.<br>Results: In the early group, infusion reactions of grades 0 (no event), 1, 2, and≥ 3 developed in 15, 1, 3, and 0 patients, respectively. In the late group, there were 26 infusion reactions of grade 0 and one of grade 3. The incidence of infusion reactions was significantly lower in the late group (p<0.05).<br>Conclusion: Cetuximab can be administered safely with avoidance of infusion reactions with the addition of hydrocortisone sodium succinate to the treatment regimen.

Journal

  • Stomato-pharyngology

    Stomato-pharyngology 28 (2), 183-186, 2015

    Japan Society of Stomato-pharyngology

Keywords

Details 詳細情報について

Report a problem

Back to top